| 148.9 2.67 (1.83%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 181.85 | 1-year : | 212.4 |
| Resists | First : | 155.69 | Second : | 181.85 |
| Pivot price | 120.32 |
|||
| Supports | First : | 116.03 | Second : | 91.51 |
| MAs | MA(5) : | 149.11 |
MA(20) : | 113.65 |
| MA(100) : | 98.29 |
MA(250) : | 65.73 |
|
| MACD | MACD : | 13.7 |
Signal : | 8.6 |
| %K %D | K(14,3) : | 87.7  |
D(3) : | 89.1 |
| RSI | RSI(14): 79.9 |
|||
| 52-week | High : | 155.69 | Low : | 34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RVMD ] has closed below upper band by 21.6%. Bollinger Bands are 304.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 149.43 - 150.33 | 150.33 - 151.2 |
| Low: | 141.08 - 142.12 | 142.12 - 143.12 |
| Close: | 147.26 - 148.84 | 148.84 - 150.34 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Wed, 22 Apr 2026
HC Wainwright Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat
Wed, 22 Apr 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Tue, 21 Apr 2026
Revolution Medicines, Inc. Bonds — Corporate Bond Rates - TradingView
Tue, 21 Apr 2026
Pancreatic cancer drug posts 58% response with chemo in early trial - Stock Titan
Tue, 21 Apr 2026
Experimental RM-055 shrank resistant tumors in pancreas, lung and colon models - Stock Titan
Tue, 21 Apr 2026
Why Revolution Medicines (RVMD) Still Looks Like a Biotech Takeover Candidate After Its $2 Billion Raise - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 209 (M) |
| Shares Float | 179 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 96 (%) |
| Shares Short | 15,410 (K) |
| Shares Short P.Month | 14,110 (K) |
| EPS | -5.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.1 % |
| Return on Equity (ttm) | -58.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -898 (M) |
| Levered Free Cash Flow | -523 (M) |
| PE Ratio | -25.07 |
| PEG Ratio | 0 |
| Price to Book value | 17.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -34.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|